alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › anti-amyloid-therapy

anti-amyloid-therapy

9 studies tagged anti-amyloid-therapy, dated 2005-01-01 to 2026-11-09. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Rapid Apolipoprotein E ε4 Proteotyping for Alzheimer's Disease Anti-Amyloid Therapy Eligibility and Risk Assessment 2026-11-09
  2. Acute Neurologic Decline in the ED: A Case Report on Recognizing ARIA in the Age of Anti-Amyloid Therapy 2026-10-31
  3. Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center 2026-10-17

Studies

9 studies carry this tag.

Date range

2005 to 2026

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • Annals of medicine and surgery (2012) 1
  • BMC neurology 1
  • CNS drugs 1
  • International journal of nanomedicine 1

9 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Rapid Apolipoprotein E ε4 Proteotyping for Alzheimer's Disease Anti-Amyloid Therapy Eligibility and Risk Assessment

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2026-11-09 Treatments

    Proteotyping reliably rules out E4/E4 homozygosity (100% NPV), enabling rapid eligibility screening for anti-amyloid therapies.

  2. Acute Neurologic Decline in the ED: A Case Report on Recognizing ARIA in the Age of Anti-Amyloid Therapy

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of education & teaching in emergency medicine 2026-10-31 Treatments

    Anti-amyloid beta (Aβ) immunotherapies are an emerging treatment for Alzheimer's disease (AD) with a rare but significant risk of amyloid-related imaging abnormalities (ARIA).

  3. Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. The journal of prevention of Alzheimer's disease 2026-10-17 Treatments

    Baseline medial temporal atrophy was associated with functional decline and microbleeds with ARIA-H. Pretreatment MRI may provide prognostic and safety information during anti-amyloid β therapy.

  4. Before the bolus: why anti-amyloid therapy must become part of every stroke code

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Annals of medicine and surgery (2012) 2026-08-21 Treatments

    Anti-amyloid monoclonal antibodies provide disease-modifying treatment options for selected patients with early symptomatic Alzheimer disease, but introduce new challenges for acute stroke care.

  5. Beyond the Cochrane review: Re-evaluating anti-amyloid therapy in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-08-01 Treatments

    The global burden of Alzheimer's disease (AD) is accelerating, with U.S. prevalence projected to reach nearly 13 million by 2060.

  6. Adverse Events as a Cause of Unblinding of Allocated Arms in Anti-Amyloid Therapy Trials: A Meta-Analysis of the Predictive Value

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. Journal of Alzheimer's disease : JAD 2024-01-01 Treatments

    Anti-amyloid drugs for early Alzheimer's disease, including lecanemab, are associated with adverse events (AEs), such as amyloid-related imaging abnormalities (ARIA)-edema/effusion (E), ARIA-hemorrhage, and infusion-related reactions, which can indicate allocated arms in clinical trials.

  7. Current Anti-Amyloid-β Therapy for Alzheimer's Disease Treatment: From Clinical Research to Nanomedicine

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. International journal of nanomedicine 2023-12-20 Treatments

    Recent successive approval of anti-amyloid-β (Aβ) monoclonal antibodies as disease-modifying therapies against Alzheimer's disease (AD) has raised great confidence in the development of anti-AD therapies; however, the current therapies still face the dilemma of significant adverse reactions and limited effects.

  8. Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. BMC neurology 2014-09-02 Treatments

    These therapies are based on the assumption that Aβ accumulation is the primary pathogenic trigger of AD.

  9. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. CNS drugs 2005-01-01 Treatments

    The leading hypothesis of the pathophysiology of Alzheimer's disease holds that the pivotal event is cleavage of the amyloid precursor protein to release intact the 42-amino-acid amyloid-beta peptide (Abeta); this hypothesis best explains the known genetic causes of Alzheimer's disease.

All topic tags with their study counts